NCT04671914

Brief Summary

Only patients who sign an informed consent will be included. Patients after a miscarriage in the 2nd trimester of pregnancy who need to perform an instrumental revision of the uterine cavity (RCUI, revisio cavi uteri instrumentalis) will be randomized into two groups. In the first group, RCUI will be performed according to current standards. In the second group, an anti-adhesive preparation with hyaluronic acid (Hyalobarrier gel Endo) will be applied to the uterine cavity at the end of the RCUI procedure. Eight to twelve weeks after the operation, the occurrence of adhesions will be evaluated by ultrasound examination and diagnostic hysteroscopy (if adhesions will be detected, they will be disrupted). The study will also include the completion of a questionnaire in terms of the frequency and strength of the menstrual cycle. The presence of adhesions will be assessed according to The American Fertility Society (AFS).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Sep 2021

Longer than P75 for phase_4

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 17, 2020

Completed
10 months until next milestone

Study Start

First participant enrolled

September 28, 2021

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2025

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

May 13, 2024

Status Verified

May 1, 2024

Enrollment Period

3.5 years

First QC Date

December 10, 2020

Last Update Submit

May 10, 2024

Conditions

Keywords

Asherman SyndromeAbortion LateHyaluronic acid gelHysteroscopy

Outcome Measures

Primary Outcomes (2)

  • Prevalence of Intrauterine adhesions after D&C and intrauterine application of hyaluronic acid gell.

    To find out wheter the application of antiadhesive agent with hyaluronic acid has an effect on the frequency of intrauterine adhesions after this procedure.

    3 month

  • Prevalence of Intrauterine adhesions after D&C.

    Dermination of the frequency of intrauterine adhesions in women who underwent instrumental revision of the uterine cavity (RCUI, revisio cavi uteri instrumentalis) after abortion in the 2nd trimester of pregnancy

    3 month

Secondary Outcomes (2)

  • Pregnancy rate

    24 month

  • Delivery rate

    24 month

Study Arms (2)

Hyaluronic acid gel after D&C

ACTIVE COMPARATOR

After abortion in the II trimester, we provide D\&C and after the procedure, we apply in uterine cavity Hyaluronic acid gel.

Drug: Hyaluronic Acid 20 MG/ML Injectable SolutionOther: Dilation and curretage

Only D&C

ACTIVE COMPARATOR

After abortion, in the II trimester, we provide only D\&C.

Other: Dilation and curretage

Interventions

Application of hyaluronic acid gel into uterine cavity after After abortion in II trimester we do D\&C

Hyaluronic acid gel after D&C

After abortion in II trimester we do D\&C.

Hyaluronic acid gel after D&COnly D&C

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Adult (18 to 40 years) women with a wish for future pregnancy
  • abortion in the 2nd trimester of pregnancy (over 12 weeks of pregnancy) with instrumental revision of the uterine cavity (RCUI)
  • signed informed consent

You may not qualify if:

  • age below 18 years, age over 40 years
  • history of previous uterine surgery (myomectomy, resection of the intrauterine septum, disruption of intrauterine adhesions)
  • suspected molar pregnancy
  • signs of pelvic infection
  • disagreement with participation in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

1.Lf Uk, Vfn

Prague, 12000, Czechia

RECRUITING

Instiue for Care of Moher and Childe

Prague, 14000, Czechia

RECRUITING

FN Bulovka

Prague, 14800, Czechia

RECRUITING

Related Publications (4)

  • Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003 Mar;79(3):577-84. doi: 10.1016/s0015-0282(02)04694-0.

  • Rai R, Regan L. Recurrent miscarriage. Lancet. 2006 Aug 12;368(9535):601-11. doi: 10.1016/S0140-6736(06)69204-0.

  • ASHERMAN JG. Amenorrhoea traumatica (atretica). J Obstet Gynaecol Br Emp. 1948 Feb;55(1):23-30. doi: 10.1111/j.1471-0528.1948.tb07045.x. No abstract available.

  • Hooker AB, de Leeuw R, van de Ven PM, Bakkum EA, Thurkow AL, Vogel NEA, van Vliet HAAM, Bongers MY, Emanuel MH, Verdonkschot AEM, Brolmann HAM, Huirne JAF. Prevalence of intrauterine adhesions after the application of hyaluronic acid gel after dilatation and curettage in women with at least one previous curettage: short-term outcomes of a multicenter, prospective randomized controlled trial. Fertil Steril. 2017 May;107(5):1223-1231.e3. doi: 10.1016/j.fertnstert.2017.02.113. Epub 2017 Apr 6.

MeSH Terms

Conditions

Gynatresia

Interventions

Hyaluronic AcidDilatation

Condition Hierarchy (Ancestors)

Genital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Diseases

Intervention Hierarchy (Ancestors)

GlycosaminoglycansPolysaccharidesCarbohydratesInvestigative Techniques

Central Study Contacts

Jiri Hanacek, MD, Ph.D.

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Participant will not be informed about usage of hyalobarier gel or not. Care provider - at the time of RCUI the surgeon will know from randomisation if apply the gel or not. The investigator performing evaluation of adhesions by hysteroscopy will be blinded to the arm which the participants belong to.
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Multicenter prospective controlled study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 10, 2020

First Posted

December 17, 2020

Study Start

September 28, 2021

Primary Completion

March 31, 2025

Study Completion

April 1, 2025

Last Updated

May 13, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations